AZTR (Azitra) EBIT: $-11.80 Mil (TTM As of Mar. 2026)


AZTR Azitra Inc AZTR
35 GF Score
Price $0.17
! 1 Warning Sign
View Full Analysis

What is Azitra EBIT?

Azitra AZTR -21.10% 35 EBIT is $-11.80 Mil as of Mar. 2026. GuruFocus rates AZTR with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Azitra's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Azitra's annualized ROC % for the quarter that ended in Mar. 2026 was -733.44%. Azitra's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,709.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Azitra's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 167.93%.

Azitra  (AMEX:AZTR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Azitra's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-15.736 * ( 1 - 0% )/( (2.509 + 1.782)/ 2 )
=-15.736/2.1455
=-733.44 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.025 - 0.565 - ( 2.068 - max(0, 1.068 - 3.019+2.068))
=2.509

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12.127 - 1.135 - ( 10.051 - max(0, 1.55 - 10.76+10.051))
=1.782

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Azitra's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.696/( ( (0.962 + max(0.009, 0)) + (0.865 + max(-0.743, 0)) )/ 2 )
=-15.696/( ( 0.971 + 0.865 )/ 2 )
=-15.696/0.918
=-1,709.80 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.81) - (0.565 + 0 + 0.237)
=0.009

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.005 + 0 + 0.555) - (1.135 + 0 + 0.168)
=-0.743

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Azitra's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-11.797/-7.025
=167.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Azitra EBIT Related Terms

Azitra EBIT Historical Data

* Premium members only.

The historical data trend for Azitra's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Azitra EBIT Chart

Azitra Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-8.87 -10.43 -11.10 -8.95 -10.94

Azitra Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -2.89 -2.76 -2.22 -3.92

AZTR vs VIVS, GRI, BIXT: EBIT Comparison

For the Biotechnology subindustry, Azitra's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azitra EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Azitra's EV-to-EBIT falls into.


AZTR
35GF Score
Azitra Inc AZTR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Azitra EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-11.80 Mil mean?
Azitra (AZTR) has a EBIT of $-11.80 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Azitra.
Is Azitra's EBIT too high?
Azitra's current EBIT is $-11.80 Mil. Overall, Azitra has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Azitra's EBIT compare to VIVS and GRI?
Azitra's EBIT of $-11.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Azitra. Azitra's current EBIT is $-11.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azitra stock overvalued right now?
Azitra (AZTR) has a current EBIT of $-11.80 Mil. The current EBIT is $-11.80 Mil. Azitra's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Azitra (AZTR), the current EBIT is $-11.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Azitra Business Description

Address 21 Business Park Drive, Branford, CT, USA, 06405
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
35GF Score

Get the complete analysis for AZTR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price